Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute.
Academies and Institutes
/ statistics & numerical data
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ adverse effects
Betacoronavirus
Brazil
/ epidemiology
COVID-19
Cancer Care Facilities
/ statistics & numerical data
Cause of Death
Child
Child, Preschool
Comorbidity
Coronavirus Infections
/ epidemiology
Diabetes Mellitus
/ epidemiology
Disease Susceptibility
Female
Hospital Mortality
Humans
Hypertension
/ epidemiology
Immunocompromised Host
Infant
Inpatients
/ statistics & numerical data
Male
Middle Aged
Neoplasms
/ drug therapy
Pandemics
Pneumonia, Viral
/ epidemiology
Retrospective Studies
SARS-CoV-2
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
08
2020
accepted:
12
10
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
11
11
2020
Statut:
epublish
Résumé
This study aimed to describe the demographic and clinical characteristics of cancer inpatients with COVID-19 exploring clinical outcomes. A retrospective search in the electronic medical records of cancer inpatients admitted to the Brazilian National Cancer Institute from April 30, 2020 to May 26, 2020 granted identification of 181 patients with COVID-19 confirmed by RT-PCR. The mean age was 55.3 years (SD ± 21.1). Comorbidities were present in 110 (60.8%) cases. The most prevalent solid tumors were breast (40 [22.1%]), gastrointestinal (24 [13.3%]), and gynecological (22 [12.2%]). Among hematological malignancies, lymphoma (20 [11%]) and leukemia (10 [5.5%]) predominated. Metastatic disease accounted for 90 (49.7%) cases. In total, 63 (34.8%) had recently received cytotoxic chemotherapy. The most common complications were respiratory failure (70 [38.7%]), septic shock (40 [22.1%]) and acute kidney injury (33 [18.2%]). A total of 60 (33.1%) patients died due to COVID-19 complications. For solid tumors, the COVID-19-specific mortality rate was 37.7% (52 out of 138 patients) and for hematological malignancies, 23.5% (8 out of 34). According to the univariate analysis COVID-19-specific mortality was significantly associated with age over 75 years (P = .002), metastatic cancer (p <0.001), two or more sites of metastases (P < .001), the presence of lung (P < .001) or bone metastases (P = .001), non-curative treatment or best supportive care intent (P < .001), higher C-reactive protein levels (P = .002), admission due to COVID-19 (P = .009), and antibiotics use (P = .02). After multivariate analysis, cases with admission due to symptoms of COVID-19 (P = .027) and with two or more metastatic sites (P < .001) showed a higher risk of COVID-19-specific death. This is the first Brazilian cohort of cancer patients with COVID-19. The rates of complications and COVID-19-specific death were significantly high.
Identifiants
pubmed: 33104715
doi: 10.1371/journal.pone.0241261
pii: PONE-D-20-26690
pmc: PMC7588058
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0241261Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Bone Marrow Transplant. 2020 Nov;55(11):2180-2184
pubmed: 32376969
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Breast Cancer Res. 2020 May 28;22(1):55
pubmed: 32460829
Healthcare (Basel). 2020 May 06;8(2):
pubmed: 32384771
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Lancet Oncol. 2020 Jul;21(7):904-913
pubmed: 32479787